GSA engineering lead resigns over DOGE ally's request for access
The lead engineer for a government text messaging service resigned Tuesday over a U.S. DOGE Service ally's request for access to sensitive data, including personal identifying information, according to two people familiar with the matter.
Steven Reilly, the engineering lead for notify.gov, left the Technology Transformation Services arm of the General Services Administration after the branch's new director, Thomas Shedd, sought administrative access to all components of the notify.gov site, the people said, speaking on the condition of anonymity to discuss personnel issues. Shedd is an eight-year Tesla alumnus who now runs the part of the GSA that hosts technologists who are deployed to provide access to a wide variety of government services, a unit he has called 'Swiss army knives.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) — AriBio Co., Ltd. ('AriBio'), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. Advertisement AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. 'This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide,' said Jai Jun Choung, CEO of AriBio. 'Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions.' 'We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries,' said Isabel Afonso, CEO of Arcera. 'This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs.' The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
USA Today
13 hours ago
- USA Today
OMN Leads Swiss Digital Marketing Revolution with AI and SEO Innovations
Winterthur, Zurich – OMN, the Swiss-based AI marketing agency, is known for delivering next-generation online marketing services tailored for Swiss businesses. More information about their innovative approaches and services can be found on their official site at OMN, a digital marketing agency based in Switzerland, is making notable progress with its AI-driven marketing and unique SEO strategies customized for the Swiss market. With 17 years of experience, this company is dedicated to changing how digital marketing is done in Switzerland. They focus on sustainable ways to acquire customers while keeping advertising spending low, using advanced technology and personalized marketing to lead this change. Central to OMN's approach is the use of AI in marketing. Their AI-powered lead generation stands out, offering more streamlined processes and optimized content through algorithms. This method helps generate qualified leads and boosts return on investment (ROI), aligning with the needs and business environment of Swiss companies. E. Niederer from OMN explained, 'Our focus on bringing AI into marketing helps us give our clients a platform that adjusts to market changes and boosts performance. We aim to create marketing solutions that fit the unique needs of the Swiss market.' OMN also excels in advanced SEO, using techniques and algorithms that have a semantic focus. They can secure top-10 search rankings within 90 days, which means better visibility for local businesses. Their approach includes semantic copywriting, link building, and neural data analysis, giving businesses an edge in the fast-changing digital world. The company's Swiss-Exclusive Strategy is tailored to optimize for the specific needs and languages of Switzerland. This customized approach has resulted in success stories for clients, proving how effective OMN's AI-driven methods are in the Swiss market. This ability to meet local needs is a major advantage, supporting the company's leadership in digital marketing innovation. Further demonstrating their commitment to transparency, OMN offers Conversion Tracking & Analytics services, tracking marketing activities with real-time data. This option allows clear measurement of ROI, and integrating AI makes the evaluation process precise and accurate for clients. E. Niederer added, 'The digital marketing scene in Switzerland is on the brink of major advancements. OMN is leading the way by using cutting-edge AI technology to help local businesses. We aim to help Swiss companies grow sustainably and build a competitive advantage.' OMN has positioned itself uniquely by focusing on the Swiss market's specific needs and challenges. This focus on local expertise boosts client satisfaction and strengthens their reputation for high standards. Going forward, OMN plans to continue innovating within digital marketing. With ongoing improvements to their AI-based strategies, the company intends to provide exceptional value and growth opportunities to their clients, driving new industry standards and inspiring changes in Switzerland and potentially beyond. Overall, OMN showcases the power of AI-driven marketing, offering Swiss businesses innovative and sustainable solutions that significantly improve ROI. Through leadership and advances in technology, the agency is committed to transforming digital marketing practices in Switzerland.
Yahoo
14 hours ago
- Yahoo
Swiss proposal mandates UBS to boost capital by $26bn
The Swiss government has proposed new capital norms, requiring UBS to increase its core capital by $26bn following its acquisition of Credit Suisse. This move aims to enhance financial stability and prevent future banking crises. The proposed regulations would mandate UBS to fully capitalise its foreign subsidiaries, reported Reuters. UBS has been given a timeframe of six to eight years to comply once the legislation is enacted. However, UBS has expressed strong opposition to the capital requirement, labelling it "extreme" and misaligned with international standards. The government indicated that the new capital requirements would allow UBS to reduce its Additional Tier 1 (AT1) bond holdings by $8bn. Currently, UBS is only required to capitalise 60% of its foreign units, with the option to use AT1 debt to meet some of its capital needs. UBS executives have raised concerns that the additional capital requirements could hinder the bank's competitiveness and impact Switzerland's status as a financial hub. The proposal follows the collapse of Credit Suisse in 2023, which prompted Swiss officials, including Finance Minister Karin Keller-Sutter, to advocate for stricter regulations to safeguard taxpayers and the economy. Keller-Sutter, who currently holds Switzerland's rotating presidency, stated that the measures are essential for the stability of the financial sector. The federal council plans to present draft proposals for stakeholder consultations in the latter half of 2025, with parliamentary approval required before the laws can take effect in 2028. However, separate ordinances could be implemented as early as 2027. UBS's Common Equity Tier 1 (CET1) capital ratio may need to rise from 14.3% to as high as 17%, surpassing that of major global competitors. UBS has indicated that it disagrees with the proposed capital increase, which it claims would necessitate holding approximately $24bn in additional CET1 capital. The Swiss government has also proposed reforms to strengthen the market regulator FINMA and improve banks' access to liquidity from the Swiss National Bank. Last month, UBS Group agreed to pay $511m to settle a US investigation into its subsidiary, Credit Suisse Group, for facilitating tax evasion among wealthy Americans. "Swiss proposal mandates UBS to boost capital by $26bn" was originally created and published by Private Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
